Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants of inter-individual variability in on-treatment platelet inhibition (e.g. CYP2C19*2), evidence that these variants have clinical utility to predict major adverse cardiovascular events remains controversial.
Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients / Lewis, J.P., Backman, J.D., Reny, J., Bergmeijer, T.O., Mitchell, B.D., Ritchie, M.D., Déry, J., Pakyz, R.E., Gong, L.i., Ryan, K., Kim, E., Aradi, D., Fernandez-Cadenas, I., Lee, M.T.M., Whaley, R.M., Montaner, J., Gensini, G.F., Cleator, J.H., Chang, K., Holmvang, L., et al.. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY. - ISSN 2055-6837. - ELETTRONICO. - 6:(2020), pp. 203-210. [10.1093/ehjcvp/pvz045]
Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients
Gensini, Gian Franco;Marcucci, Rossella;Giusti, Betti;
2020
Abstract
Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants of inter-individual variability in on-treatment platelet inhibition (e.g. CYP2C19*2), evidence that these variants have clinical utility to predict major adverse cardiovascular events remains controversial.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lewis 2020.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
972.8 kB
Formato
Adobe PDF
|
972.8 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
